Literature DB >> 26910051

Acute myeloid leukemia: advancing clinical trials and promising therapeutics.

Naval Daver1, Jorge Cortes1, Hagop Kantarjian1, Farhad Ravandi1.   

Abstract

Recent progress in understanding the biology of acute myeloid leukemia (AML) and the identification of targetable driver mutations, leukemia specific antigens and signal transduction pathways has ushered in a new era of therapy. In many circumstances the response rates with such targeted or antibody-based therapies are superior to those achieved with standard therapy and with decreased toxicity. In this review we discuss novel therapies in AML with a focus on two major areas of unmet need: (1) single agent and combination strategies to improve frontline therapy in elderly patients with AML and (2) molecularly targeted therapies in the frontline and salvage setting in all patients with AML.

Entities:  

Keywords:  AML; clinical trials; molecular therapy; monoclonal antibodies; multikinase inhibitors

Mesh：

Substances：

Year:  2016        PMID： 26910051      PMCID： PMC5006674          DOI： 10.1586/17474086.2016.1158096

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN： 1747-4094            Impact factor:   2.929


  89 in total

Review 1.  Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia.

Authors:  Charles L Sawyers
Journal:  Cancer Cell       Date:  2002-06       Impact factor: 31.743

2.  Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.

Authors:  Jean-Pierre J Issa; Gail Roboz; David Rizzieri; Elias Jabbour; Wendy Stock; Casey O'Connell; Karen Yee; Raoul Tibes; Elizabeth A Griffiths; Katherine Walsh; Naval Daver; Woonbok Chung; Sue Naim; Pietro Taverna; Aram Oganesian; Yong Hao; James N Lowder; Mohammad Azab; Hagop Kantarjian
Journal:  Lancet Oncol       Date:  2015-08-19       Impact factor: 41.316

3.  Cell-cycle control during development: taking it up a notch.

Authors:  Barbara J Thomas
Journal:  Dev Cell       Date:  2005-04       Impact factor: 12.270

4.  Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.

Authors:  Marina Konopleva; Rooha Contractor; Twee Tsao; Ismael Samudio; Peter P Ruvolo; Shinichi Kitada; Xingming Deng; Dayong Zhai; Yue-Xi Shi; Thomas Sneed; Monique Verhaegen; Maria Soengas; Vivian R Ruvolo; Teresa McQueen; Wendy D Schober; Julie C Watt; Tilahun Jiffar; Xiaoyang Ling; Frank C Marini; David Harris; Martin Dietrich; Zeev Estrov; James McCubrey; W Stratford May; John C Reed; Michael Andreeff
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

5.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

6.  Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.

Authors:  Gautam Borthakur; Hagop Kantarjian; Farhad Ravandi; Weiguo Zhang; Marina Konopleva; John J Wright; Stefan Faderl; Srdan Verstovsek; Sheela Mathews; Michael Andreeff; Jorge E Cortes
Journal:  Haematologica       Date:  2010-10-15       Impact factor: 9.941

7.  Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.

Authors:  Hagop Kantarjian; Farhad Ravandi; Susan O'Brien; Jorge Cortes; Stefan Faderl; Guillermo Garcia-Manero; Elias Jabbour; William Wierda; Tapan Kadia; Sherry Pierce; Jianqin Shan; Michael Keating; Emil J Freireich
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

8.  A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.

Authors:  N Daver; H Kantarjian; F Ravandi; E Estey; X Wang; G Garcia-Manero; E Jabbour; M Konopleva; S O'Brien; S Verstovsek; T Kadia; C Dinardo; S Pierce; X Huang; N Pemmaraju; M Diaz-Pines-Mateo; J Cortes; G Borthakur
Journal:  Leukemia       Date:  2015-09-14       Impact factor: 11.528

9.  Crenolanib is a selective type I pan-FLT3 inhibitor.

Authors:  Catherine Choy Smith; Elisabeth A Lasater; Kimberly C Lin; Qi Wang; Melissa Quino McCreery; Whitney K Stewart; Lauren E Damon; Alexander E Perl; Grace R Jeschke; Mayumi Sugita; Martin Carroll; Scott C Kogan; John Kuriyan; Neil P Shah
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-12       Impact factor: 11.205

10.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

Authors:  Wei Xu; Hui Yang; Ying Liu; Ying Yang; Ping Wang; Se-Hee Kim; Shinsuke Ito; Chen Yang; Pu Wang; Meng-Tao Xiao; Li-xia Liu; Wen-qing Jiang; Jing Liu; Jin-ye Zhang; Bin Wang; Stephen Frye; Yi Zhang; Yan-hui Xu; Qun-ying Lei; Kun-Liang Guan; Shi-min Zhao; Yue Xiong
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 38.585
View more
  3 in total

1.  Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy.

Authors:  Paola Dama; Marshall Tang; Noreen Fulton; Justin Kline; Hongtao Liu
Journal:  J Immunother Cancer       Date:  2019-07-10       Impact factor: 13.751

2.  High expression levels and the C3435T SNP of the ABCB1 gene are associated with lower survival in adult patients with acute myeloblastic leukemia in Mexico City.

Authors:  Irma Olarte Carrillo; Anel Irais García Laguna; Adrián De la Cruz Rosas; Christian Omar Ramos Peñafiel; Juan Collazo Jaloma; Adolfo Martínez Tovar
Journal:  BMC Med Genomics       Date:  2021-10-26       Impact factor: 3.063

3.  Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next-generation sequencing technique.

Authors:  Rui-Qi Wang; Chong-Jian Chen; Yu Jing; Jia-Yue Qin; Yan Li; Guo-Feng Chen; Wei Zhou; Yong-Hui Li; Juan Wang; Da-Wei Li; Hong-Mei Zhao; Bian-Hong Wang; Li-Li Wang; Hong Wang; Meng-Zhen Wang; Xiao-Ning Gao; Li Yu
Journal:  Cancer Med       Date:  2020-09-24       Impact factor: 4.452
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.